Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPEC: 2 vs 4 Cycles Neoadjuvant CAPOX in Rectal Cancer
NCT04922853Phase 3Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in rectal cancer, sponsored by West China Hospital of Sichuan University. Started Aug 2021; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04922853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922853.